Early screening method and kit for non-alcoholic fatty liver disease susceptibility genes

A fatty liver disease and susceptibility gene technology, applied in the field of early screening methods and kits for non-alcoholic fatty liver disease susceptibility genes

Active Publication Date: 2021-06-25
北京科力丹迪生物医疗科技有限公司
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no very effective early detection method in clinical practice, so it is urgent to establish a highly sensitiv...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Early screening method and kit for non-alcoholic fatty liver disease susceptibility genes
  • Early screening method and kit for non-alcoholic fatty liver disease susceptibility genes
  • Early screening method and kit for non-alcoholic fatty liver disease susceptibility genes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Feasibility analysis of SNP site screening of human non-alcoholic fatty liver disease susceptibility-related genes

[0094] By searching NCBI home and abroad genome-wide association study (genome-wide association study, GWAS) in large-scale pathological control group clinical research of the relevant sites of non-alcoholic fatty liver disease, the inventors screened and Evaluation, selected 10 single nucleotide polymorphism sites that are significantly associated with the risk of non-alcoholic fatty liver disease in the Chinese population, and are independent of each other, there is no linkage disequilibrium, so the site selection of the present invention is representative , independence and cumulative risk value, which can be used to assess the risk of individuals suffering from non-alcoholic fatty liver disease.

[0095] The screened SNP sites are as follows:

[0096]rs738409, rs58542926, rs780094, rs641738, rs72613567, rs3480, rs7674434, rs12152703, rs5764455, rs600...

Embodiment 2

[0097] Embodiment 2 system verification

[0098] System validation includes accuracy, specificity, sensitivity, precision, and comparison among personnel.

[0099] Accuracy verification scheme: 20 cases were detected at each site, compared with Sanger sequencing, the expected target was 95%.

[0100] Specificity Validation Protocol: Included in Accuracy, expected target 95%.

[0101] Sensitive verification scheme: using human genomic DNA positive samples as templates, the DNA contents of calibration samples were 1ng / μL, 5ng / μL, 10ng / μL, 50ng / μL, and 100ng / μL for sensitivity inspection.

[0102] The precision verification plan (including intra-batch, inter-batch, and personnel comparisons, not involving inter-instrument comparisons) has an expected target of 95%.

[0103] Intra-assay precision: The same batch of each sample was repeated 3 times to compare the intra-assay precision.

[0104] Inter-batch precision: The same operator tests the same sample in multiple batches to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an early screening method and a kit for non-alcoholic fatty liver disease susceptibility genes. In particular, the difference of non-alcoholic fatty liver disease gene spectrums of Chinese people and European and American people is considered, and a combination of SNP loci of genes related to non-alcoholic fatty liver disease susceptibility of Chinese people is screened out; wide (high-throughput detection sites and high-throughput detection samples) screening and inspection are carried out on genetic markers related to the non-alcoholic fatty liver disease by using a nucleic acid mass spectrometer. The method disclosed by the invention is high in detection success rate, good in technical reproducibility and high in cost performance, can realize multi-gene detection of a single small sample, and meets maximum use of the small sample; The method has the technical advantages of high accuracy and high sensitivity, the detection result is stable, and the detection positive rate is increased.

Description

technical field [0001] The invention belongs to the field of biological technology, in particular, the invention relates to an early screening method and kit for susceptibility genes of non-alcoholic fatty liver disease. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) refers to a clinicopathological syndrome characterized by excessive fat deposition in liver cells caused by alcohol and other definite liver-damaging factors, and is closely related to insulin resistance and genetic susceptibility. Metabolic stress-induced liver injury. Non-alcoholic fatty liver disease has become an important cause of chronic liver disease in developed countries such as Europe and the United States and in wealthy areas of my country. The prevalence of NAFLD in ordinary adults is 10% to 30%, of which 10% to 20% are NASH, and the latter will cirrhosis within 10 years. The incidence rate is as high as 25%. In the past 10 years, more and more studies have revealed the corr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883C12Q1/686C12Q1/6872C12N15/11
CPCC12Q1/6883C12Q1/686C12Q1/6872C12Q2600/156C12Q2537/143
Inventor 徐力
Owner 北京科力丹迪生物医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap